Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Litarex
2. Monolithium Citrate
1. 919-16-4
2. Trilithium Citrate
3. Litarex
4. Citric Acid Trilithium Salt
5. Lithium Citrate Anhydrous
6. Lithium (citrate)
7. Citric Acid, Trilithium Salt
8. Lithium Citrate (anhydrous)
9. Lithium Citrate Tribasic Tetrahydrate
10. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-, Trilithium Salt
11. Anhydrous Lithium Citrate
12. Demalit; Litarex; Lithonate S
13. 6680-58-6
14. Demalit
15. Chebi:64735
16. Lithium 2-hydroxypropane-1,2,3-tricarboxylate
17. Trilithium;2-hydroxypropane-1,2,3-tricarboxylate
18. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-, Lithium Salt (1:3)
19. Einecs 213-045-8
20. Citric Acid, Lithium Salt
21. Trilithium 2-hydroxypropane-1,2,3-tricarboxylate
22. Einecs 233-819-9
23. Anh. Lithium Citrate
24. Unii-3655633623
25. Lithium Citrate (anh.)
26. Citric Acid,lithium Salt
27. Lithium Citrate [mi]
28. Spectrum1504269
29. Chembl1201170
30. Dtxsid70883185
31. Hms1923k13
32. Hms2093g04
33. Lithium Citrate Tribasic 4-hydrate
34. 2-hydroxy-1,2,3-propanetricarboxylic Acid Lithium Salt (1:3)
35. Akos015839591
36. Akos015902460
37. Ccg-213298
38. Db14507
39. Ncgc00095267-01
40. Ncgc00095267-02
41. 1313437-84-1
42. Db-054961
43. Ft-0636234
44. Lithium2-hydroxypropane-1,2,3-tricarboxylate
45. Lithium 3-carboxy-3,5-dihydroxy-5-oxopentanoate
46. Q2351742
Molecular Weight | 210.0 g/mol |
---|---|
Molecular Formula | C6H5Li3O7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 2 |
Exact Mass | 210.0515378 g/mol |
Monoisotopic Mass | 210.0515378 g/mol |
Topological Polar Surface Area | 141 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 211 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 4 |
1 of 2 | |
---|---|
Drug Name | Lithium citrate |
Active Ingredient | Lithium citrate |
Dosage Form | Syrup |
Route | Oral |
Strength | eq 300mg carbonate/5ml |
Market Status | Prescription |
Company | Wockhardt; Roxane |
2 of 2 | |
---|---|
Drug Name | Lithium citrate |
Active Ingredient | Lithium citrate |
Dosage Form | Syrup |
Route | Oral |
Strength | eq 300mg carbonate/5ml |
Market Status | Prescription |
Company | Wockhardt; Roxane |
Lithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment.
Although lithium has been used for over 50 years in treatment of bipolar disorder, the mechanism of action is still unknown. Lithium's therapeutic action may be due to a number of effects, ranging from inhibition of enzymes such as glycogen synthase kinase 3, inositol phosphatases, or modulation of glutamate receptors.
The precise mechanism of action of Li+ as a mood-stabilizing agent is currently unknown. It is possible that Li+ produces its effects by interacting with the transport of monovalent or divalent cations in neurons. An increasing number of scientists have come to the conclusion that the excitatory neurotransmitter glutamate is the key factor in understanding how lithium works. Lithium has been shown to change the inward and outward currents of glutamate receptors (especially GluR3), without a shift in reversal potential. Lithium has been found to exert a dual effect on glutamate receptors, acting to keep the amount of glutamate active between cells at a stable, healthy level, neither too much nor too little. It is postulated that too much glutamate in the space between neurons causes mania, and too little, depression. Another mechanism by which lithium might help to regulate mood include the non-competitive inhibition of an enzyme called inositol monophosphatase. Alternately lithium's action may be enhanced through the deactivation of the GSK-3B enzyme. The regulation of GSK-3B by lithium may affect the circadian clock. GSK-3 is known for phosphorylating and thus inactivating glycogen synthase. GSK-3B has also been implicated in the control of cellular response to damaged DNA. GSK-3 normally phosphorylates beta catenin, which leads to beta catenin degratation. When GSK-3 is inhibited, beta catenin increases and transgenic mice with overexpression of beta catenin express similar behaviour to mice treated with lithium. These results suggest that increase of beta catenin may be a possible pathway for the therapeutic action of lithium.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37189
Submission : 2022-06-17
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1320
Submission : 1969-02-10
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Lithium Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lithium Citrate, including repackagers and relabelers. The FDA regulates Lithium Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lithium Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lithium Citrate supplier is an individual or a company that provides Lithium Citrate active pharmaceutical ingredient (API) or Lithium Citrate finished formulations upon request. The Lithium Citrate suppliers may include Lithium Citrate API manufacturers, exporters, distributors and traders.
click here to find a list of Lithium Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lithium Citrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Lithium Citrate active pharmaceutical ingredient (API) in detail. Different forms of Lithium Citrate DMFs exist exist since differing nations have different regulations, such as Lithium Citrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lithium Citrate DMF submitted to regulatory agencies in the US is known as a USDMF. Lithium Citrate USDMF includes data on Lithium Citrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lithium Citrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lithium Citrate suppliers with USDMF on PharmaCompass.
Lithium Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lithium Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lithium Citrate GMP manufacturer or Lithium Citrate GMP API supplier for your needs.
A Lithium Citrate CoA (Certificate of Analysis) is a formal document that attests to Lithium Citrate's compliance with Lithium Citrate specifications and serves as a tool for batch-level quality control.
Lithium Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Lithium Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lithium Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Lithium Citrate EP), Lithium Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lithium Citrate USP).
LOOKING FOR A SUPPLIER?